What’s on your Summer #CTBucketList?

Eli Lilly buying Loxo Oncology for about $8 billion

Traders work the floor of the New York Stock Exchange October 23, 2002 in New York City. (Spencer Platt/Getty Images)

STAMFORD — Eli Lilly is buying Loxo Oncology for about $8 billion, broadening its lineup of cancer treatments.

Loxo Oncology Inc., based in Stamford, is a biopharmaceutical company focused on the development and commercialization of medicines for patients with genomically defined cancers.

Eli Lilly and Co. said Monday that it will pay $235 for each Loxo share. That’s a 68 percent premium to the company’s Friday closing price of $139.87.

The deal is expected to close by the end of the first quarter.

Shares of Eli Lilly, based in Indianapolis, fell 2.7 percent in Monday premarket trading.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.